Article Detail - JE Part B
Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58718) Final Billing and Coding Article - Effective August 08, 2022
This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).
Medicare Coverage Database (MCD) Number/Contractor Determination Number: A58718
Billing and Coding Article Title: Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
Effective Date: August 08, 2022
Summary of LCA: The information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer L39005
Visit the Proposed LCDs webpage to access this Billing and Coding Article.